Gilead, Kite shorten Yescarta manufacturing by two days in 'incremental' improvement
Gilead and Kite announced Tuesday it received FDA approval to shorten its manufacturing process for the cell therapy Yescarta, a move expected to reduce the time patients need to wait for the treatment by two days.
The shortening, measured by what’s known as “median turnaround time (TAT),” will fall from 16 days to 14 days, Gilead estimates. David Porter, the director of cell therapy and transplants at Penn Medicine, told Endpoints News any improvement in median TAT is good, but Tuesday’s update represents one that is “incremental.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.